Novo Nordisk hikes 2026 outlook again as Wegovy pill beats forecasts

2

By Jacob Gronholt-Pedersen and Patrick Wingrove COPENHAGEN, Nov 4 (Reuters) – Obesity drugmaker Novo Nordisk raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)